MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.82
-0.59
-3.60%
After Hours: 15.82 0 0.00% 16:00 07/10 EDT
OPEN
16.42
PREV CLOSE
16.41
HIGH
16.42
LOW
15.43
VOLUME
137.81K
TURNOVER
--
52 WEEK HIGH
21.92
52 WEEK LOW
6.95
MARKET CAP
472.61M
P/E (TTM)
-7.8793
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRRK stock price target is 28.25 with a high estimate of 35.00 and a low estimate of 22.00.

EPS

SRRK News

More
Scholar Rock Holding (SRRK) Presents At BMO Capital Markets Healthcare Conference - Slideshow
Seeking Alpha - Article · 06/24 18:46
Scholar Rock to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Business Wire · 06/16 21:05
Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting
Business Wire · 06/12 12:30
Scholar Rock To Present Clinical And Preclinical Data For SRK-015 At 2020 Virtual Cure SMA Research And Clinical Care Meeting Jun. 12
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
Benzinga · 06/12 11:31
Hedge Funds Are Dumping Scholar Rock Holding Corporation (SRRK)
Insider Monkey · 06/10 19:39
Scholar Rock to Present at the Jefferies Virtual Global Healthcare Conference
Business Wire · 05/27 21:30
Scholar Rock Appoints Tony Kingsley to Its Board of Directors
Business Wire · 05/21 21:30
Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference
Business Wire · 05/18 12:30

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About SRRK

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.
More

Webull offers kinds of Scholar Rock Holding Corp stock information, including NASDAQ:SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.